BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cengent Therapeutics Signs Genes To Leads Drug Discovery Contract With Novartis (NVS)


10/19/2005 5:10:50 PM

SAN DIEGO--(BUSINESS WIRE)--April 12, 2004--Cengent Therapeutics, a structure-guided drug discovery company, announced today the signing of a Genes To Leads® drug discovery contract with the Novartis Institutes for BioMedical Research site in Basel, Switzerland (Novartis Pharma AG). Under the agreement, Cengent will apply its proprietary structure-based lead identification technology to screen for drug candidates against multiple targets identified by the Novartis Institutes. Financial terms were not disclosed, but include up-front and milestone payments.

Genes To Leads is a compound lead generation service that greatly accelerates and optimizes drug discovery. Using an identified drug target, Genes To Leads selects closely related structural proteins (anti-targets) for analysis using complementary structure-based and sequence-based methods. This analysis of targets and anti-targets incorporates selectivity into identified leads, improving odds of a successful lead optimization candidate. Differential dynamic pharmacophores are defined for the protein target and anti-targets by analyzing the flexibility of putative binding sites. The functional relationships required for a ligand to bind are better defined from this dynamic pharmacophoric analysis of both targets and anti-targets. Finally, a query that can be used to search commercial compound databases, proprietary databases, or virtual databases is generated with results filtered to match customer requirements. This process provides maximum flexibility to the customer in terms of scope of compound search as well as "hit" requirements.

The Genes To Leads technology has been successfully applied to 15 targets on a contract basis for a growing number of pharmaceutical and biotech companies, and is the basis for Cengent's own highly successful in-house programs for orally active PTP-1B inhibitors (for treatment of type II diabetes and obesity), and anthrax lethal factor inhibitors.

About Cengent Therapeutics

Cengent Therapeutics is a structure-based drug discovery company with in-house pre-clinical programs in obesity/diabetes, anti-infectives and oncology. The company also provides a comprehensive suite of structural services and capabilities for accelerating and optimizing the drug discovery process for its pharmaceutical and biotechnology partners and clients. The company's service and product offerings include: Genes To Leads to accelerate lead discovery and target validation; Structure Determination Services, including X-ray crystallography and augmented homology modeling; and StructureBank®, a database for the large-scale comparative analysis of protein targets and anti-targets. For additional information, visit our Web site at www.cengent.com.

Contact:

Cengent Therapeutics Inc. Dr. Lance J. Ransom Wright, Senior Director, Product Technology and Marketing, 858-675-2400 lance@cengent.com

Source: Cengent Therapeutics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES